Abstract
We evaluated a serial change in peripheral neuropathy (PN) severity during treatment with bortezomib (Bor) or lenalidomide (Len) using the Functional Assessment of Cancer Therapy scale/Gynecologic Oncology Group-Neurotoxicity (FACT/GOG-Ntx). The patient suffered from grade 2 PN and exhibited a dramatic decrease in FACT/GOG-Ntx score after intravenous and subcutaneous Bor therapy. Thereafter, he received seven cycles of Len therapy, which exacerbated existing PN; he experienced mild numbness and exhibited a transient decrease in FACT/GOG-Ntx score. Interestingly, FACT/GOG-Ntx score increased to baseline and numbness was ameliorated during the Len washout period in every cycle.
| Original language | English |
|---|---|
| Pages (from-to) | 1651-1653 |
| Number of pages | 3 |
| Journal | Internal Medicine |
| Volume | 53 |
| Issue number | 15 |
| DOIs | |
| Publication status | Published - Jan 1 2014 |
Fingerprint
All Science Journal Classification (ASJC) codes
- Internal Medicine
Cite this
Peripheral neuropathy exacerbated by lenalidomide in a patient with multiple myeloma. / Kamimura, Tomohiko; Miyamoto, Toshihiro; Yokota, Noriko; Aoki, Takatoshi; Ito, Yoshikiyo; Akashi, Koichi.
In: Internal Medicine, Vol. 53, No. 15, 01.01.2014, p. 1651-1653.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Peripheral neuropathy exacerbated by lenalidomide in a patient with multiple myeloma
AU - Kamimura, Tomohiko
AU - Miyamoto, Toshihiro
AU - Yokota, Noriko
AU - Aoki, Takatoshi
AU - Ito, Yoshikiyo
AU - Akashi, Koichi
PY - 2014/1/1
Y1 - 2014/1/1
N2 - We evaluated a serial change in peripheral neuropathy (PN) severity during treatment with bortezomib (Bor) or lenalidomide (Len) using the Functional Assessment of Cancer Therapy scale/Gynecologic Oncology Group-Neurotoxicity (FACT/GOG-Ntx). The patient suffered from grade 2 PN and exhibited a dramatic decrease in FACT/GOG-Ntx score after intravenous and subcutaneous Bor therapy. Thereafter, he received seven cycles of Len therapy, which exacerbated existing PN; he experienced mild numbness and exhibited a transient decrease in FACT/GOG-Ntx score. Interestingly, FACT/GOG-Ntx score increased to baseline and numbness was ameliorated during the Len washout period in every cycle.
AB - We evaluated a serial change in peripheral neuropathy (PN) severity during treatment with bortezomib (Bor) or lenalidomide (Len) using the Functional Assessment of Cancer Therapy scale/Gynecologic Oncology Group-Neurotoxicity (FACT/GOG-Ntx). The patient suffered from grade 2 PN and exhibited a dramatic decrease in FACT/GOG-Ntx score after intravenous and subcutaneous Bor therapy. Thereafter, he received seven cycles of Len therapy, which exacerbated existing PN; he experienced mild numbness and exhibited a transient decrease in FACT/GOG-Ntx score. Interestingly, FACT/GOG-Ntx score increased to baseline and numbness was ameliorated during the Len washout period in every cycle.
UR - http://www.scopus.com/inward/record.url?scp=84905229939&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84905229939&partnerID=8YFLogxK
U2 - 10.2169/internalmedicine.53.1354
DO - 10.2169/internalmedicine.53.1354
M3 - Article
C2 - 25088880
AN - SCOPUS:84905229939
VL - 53
SP - 1651
EP - 1653
JO - Internal Medicine
JF - Internal Medicine
SN - 0918-2918
IS - 15
ER -